Navigation Links
Penn study identifies genes that may help predict response to BRAF inhibitors for advanced melanoma
Date:6/1/2011

(CHICAGO) -- Genetic analysis of the tumors from patients with advanced melanoma can clue researchers in to how well patients will respond to a therapy that targets the growth-promoting protein called BRAF, a researcher from the Perelman School of Medicine at the University of Pennsylvania will report on Monday, June 6 at the annual meeting of the American Society of Clinical Oncology. Looking outside of the BRAF gene, the researchers found loss of the tumor suppressor gene PTEN also appears to be associated with patient response to GSK436, which could help guide researchers to even more personalized approaches to melanoma therapy.

The phase I clinical trial data highlight the role that genetic changes other than that in BRAF may play in a patient's resistance to BRAF inhibitors, a targeted therapy that has shown unprecedented efficacy among patients with metastatic disease.

"These findings are important because they suggest that performing genetic characterization of melanomas for genetic changes outside of BRAF could help predict the patients that may have worse responses to BRAF inhibitors," says Katherine Nathanson, MD, an associate professor of Medical Genetics in Penn's Abramson Cancer Center, who led the study. Armed with such information, a physician could prescribe a different drug or combination of drugs to target these advanced cancers. Guiding such decisions early can save time in the race to control metastatic melanomas, which commonly kill patients within a year after they're identified.

An estimated 40 to 60 percent of all melanomas carry a mutated BRAF gene. Although patients with advanced melanoma are often resistant to chemotherapy, drugs that go after the overactive BRAF protein which acts as a foot on a gas pedal promoting tumor growth -- have demonstrated promising results in Phase I and II trials. Research shows that as many as 80 percent of patients who take these drugs experience a clinical benefit. However,
'/>"/>

Contact: Holly Auer
holly.auer@uphs.upenn.edu
215-200-2313
University of Pennsylvania School of Medicine
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Despite Treatment, Employees with Depression Generate Higher Absentee Costs, According to Thomson Reuters Study
2. American Council on Exercise (ACE) Study Reveals Kettlebells Provide Powerful Workout in Short Amount of Time
3. TV drama can be more persuasive than news program, study finds
4. Study carried out into biological risks of eating reptiles
5. Neuroimaging study may pave way for effective Alzheimers treatments
6. Study finds racial gaps continue in heart disease awareness
7. Luth Researchs IndicatorEDG(TM) Study Finds Americans Hopes of Achieving Their Dreams Are Fading
8. First blinded study of venous insufficiency prevalence in MS shows promising results
9. Soothing infants with food focus of childhood obesity study
10. People with anxiety disorder less able to regulate response to negative emotions, study shows
11. American Heart Association Rapid Access Journal Report: Study Finds Racial Gaps Continue in Heart Disease Awareness, Low Knowledge of Heart Attack Warning Signs Among Women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... July 31, 2015 , ... Intellitec Solutions ... recent implementation of Microsoft Dynamics GP for a senior living facility in Maine. ... supporting senior living communities in 16 states. This further expansion was again a ...
(Date:7/30/2015)... Tucson, AZ (PRWEB) , ... July 31, 2015 , ... ... getaways may seem impossible or out-of-reach. The questions race through your mind: What happens ... is a storm? You feel overwhelmed and cancel your plans. , But not taking ...
(Date:7/30/2015)... (PRWEB) , ... July 31, 2015 , ... On July ... meeting in Manatee county to discuss plausible solutions for controlling the heroin outbreak. Ultimately ... event of an overdose is largely perpetuating the heroin crisis in North Florida. The ...
(Date:7/30/2015)... Texas (PRWEB) , ... July 30, 2015 , ... ... Path Institute (C-Path), and TransCelerate BioPharma, Inc. are pleased to announce that data ... have been published for use on the CDISC website . These three ...
(Date:7/30/2015)... ... July 30, 2015 , ... Women's dating coach Simone ... It's for women interested in improving their love lives using specific "lines" designed ... launched to the public early this morning, has drawn praise from several dating ...
Breaking Medicine News(10 mins):Health News:Intellitec Solutions Expands Long term Care ERP Offerings to Maine 2Health News:Aging Life Care Association™ Experts Offer Tips for Caregivers in Need of Vacation Time 2Health News:Aging Life Care Association™ Experts Offer Tips for Caregivers in Need of Vacation Time 3Health News:Manatee County’s Opioid Task Force Calls for More Funding and Face to Face Counseling After Overdose 2Health News:Manatee County’s Opioid Task Force Calls for More Funding and Face to Face Counseling After Overdose 3Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 2Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 3Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 4Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 5Health News:Lovetraction Lines - Review Examining Simone Myers' New Online Course Released 2
... Conference Call at 10 a.m. EST, January 28, 2008, ... IMA ) and Matria Healthcare, Inc. (Nasdaq: ... definitive agreement pursuant to,which Inverness will acquire all outstanding ... payable $6.50 in cash plus $32.50 in,convertible preferred stock ...
... Surgeons, Jolie, Kidman, Anderson, Loren, Bundchen, Pitt, and ... hear it every day, "Oh, I wish I,could look ... I,d do anything.",With increasing availability of aesthetic plastic surgery, ... some of these wishes are coming true. But do ...
... the first and only co-formulated protease ... use in children with HIV, ABBOTT PARK, Ill., ... that the European Committee for Medicinal Products for Human ... (EMEA),has issued a positive opinion recommending approval of a ...
... Shazaaam! LLC, an integrated,marketing communications agency headquartered ... and Marketing Communications Agency of,Record for Enuresis ... social marketing, proactive and reactive,blogging, traditional and ... and visibility among its target market., ...
... Germany, January 28 Gerresheimer,AG has quickly completed ... Dusseldorf manufacturer of glass and plastic products for ... it continues its global expansion, on 21 December ... Valencia) and Argentina (Buenos,Aires) specialises in pharma containers ...
... The Department of Defense has commissioned a nine-month study ... Medical Center to determine whether a new drug based ... of acute radiation injury following radiation exposure. The new ... was greater than 5,000 times more effective at reducing ...
Cached Medicine News:Health News:Inverness Medical Innovations Enters Into a Definitive Agreement to Acquire Matria Healthcare, Inc. 2Health News:Inverness Medical Innovations Enters Into a Definitive Agreement to Acquire Matria Healthcare, Inc. 3Health News:Inverness Medical Innovations Enters Into a Definitive Agreement to Acquire Matria Healthcare, Inc. 4Health News:Inverness Medical Innovations Enters Into a Definitive Agreement to Acquire Matria Healthcare, Inc. 5Health News:Inverness Medical Innovations Enters Into a Definitive Agreement to Acquire Matria Healthcare, Inc. 6Health News:Celebrity Influences on Plastic Surgery 2Health News:Celebrity Influences on Plastic Surgery 3Health News:Celebrity Influences on Plastic Surgery 4Health News:Abbott's Kaletra(R) and Aluvia(R) (lopinavir/ritonavir) New Lower-Strength Tablet for Pediatric Use Receives Positive Opinion from EMEA 2Health News:Abbott's Kaletra(R) and Aluvia(R) (lopinavir/ritonavir) New Lower-Strength Tablet for Pediatric Use Receives Positive Opinion from EMEA 3Health News:Abbott's Kaletra(R) and Aluvia(R) (lopinavir/ritonavir) New Lower-Strength Tablet for Pediatric Use Receives Positive Opinion from EMEA 4Health News:Abbott's Kaletra(R) and Aluvia(R) (lopinavir/ritonavir) New Lower-Strength Tablet for Pediatric Use Receives Positive Opinion from EMEA 5Health News:Abbott's Kaletra(R) and Aluvia(R) (lopinavir/ritonavir) New Lower-Strength Tablet for Pediatric Use Receives Positive Opinion from EMEA 6Health News:Abbott's Kaletra(R) and Aluvia(R) (lopinavir/ritonavir) New Lower-Strength Tablet for Pediatric Use Receives Positive Opinion from EMEA 7Health News:Abbott's Kaletra(R) and Aluvia(R) (lopinavir/ritonavir) New Lower-Strength Tablet for Pediatric Use Receives Positive Opinion from EMEA 8Health News:Shazaaam! Named PR Agency of Record for Enuresis Treatment Center 2Health News:Feds fund study of drug that may prevent radiation injury 2
(Date:7/30/2015)... Tianyin Pharmaceutical Inc. (NYSE Amex: TPI ... the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded ... the notice it received on May 21, 2015 from ... Company was below certain of the Exchange,s continued listing ... of the NYSE MKT Company Guide, due to the ...
(Date:7/30/2015)... COTTAGE, New York , July 30, 2015 /PRNewswire/ ... release of its latest report titled, "Continuous Glucose Monitoring ... - 2020". According to the report, the global continuous ... Mn in 2014 and is expected to reach US$ ... during the forecast period, 2015 to 2020. ...
(Date:7/30/2015)... MIAMI , July 30, 2015   ... latest update to UNI®, the world,s first operating ... simulators, is now available exclusively to Gaumard users. ... for recently launched Newborn Tory™ S2200, as well ... and monitoring of clinical measures such as EtCO ...
Breaking Medicine Technology:TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 4Gaumard's Latest UNI Operating System Update Adds Performance and New Functionality 2Gaumard's Latest UNI Operating System Update Adds Performance and New Functionality 3
... N.J., Jan. 18, 2011 Fenwal, Inc. of Lake ... they have signed an agreement under which Fenwal will ... blood centers, plasma centers and hospitals in the United ... such as Genesis™ blood collection mixers and monitors, RapidSeal ...
... Inc. announced today that the U.S. Food & ... clearance to market the SImmetry™ Sacroiliac Joint Fusion ... intended for treating conditions including degenerative sacroiliitis and ... System consists of a range of threaded, cannulated ...
Cached Medicine Technology:Fenwal, GenesisBPS Enter Agreement for Blood-Specialty Products 2Zyga Technology, Inc. Receives FDA 510(K) Clearance for the SImmetry™ Sacroiliac Joint Fusion System 2
This modular benchtop fume hood ventilates and purifies chemical fumes, allowing safe indoor release of exhaust. Bonded charcoal filters remove most organic contaminants. Options include final HEPA f...
... proof polypropylene exhaust hoods are designed to ... and draw a stream of air across ... the operator. Other sizes and types of ... double-slot are available on special order in ...
... This fume hood is the ... but includes a flat internal ... the shell. The baffle slopes ... air flow to sweep the ...
... polypropylene exhaust hoods are designed to rest ... draw a stream of air across the ... operator. Other sizes and types of hoods ... are available on special order in materials ...
Medicine Products: